| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14787210.2015.1093934 |
| P698 | PubMed publication ID | 26414781 |
| P50 | author | Resat Ozaras | Q95277634 |
| P2093 | author name string | Burak Isal | |
| Goknil Gultekin | |||
| Hawa'a Khodor | |||
| Nergul Yetim | |||
| Umut Kaan Unal | |||
| Yunus Emre Demirhan | |||
| P2860 | cites work | Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy | Q27005159 |
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B | Q28212394 | ||
| Telbivudine versus lamivudine in patients with chronic hepatitis B | Q28261708 | ||
| EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 | ||
| Chronic hepatitis B: update 2009 | Q29617409 | ||
| The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation | Q33365990 | ||
| Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy | Q33417353 | ||
| Trends in waiting list registration for liver transplantation for viral hepatitis in the United States | Q34021608 | ||
| Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study | Q34317204 | ||
| Interferon for hepatitis B: US experience | Q34375772 | ||
| Chemotherapy-related reactivation of hepatitis B infection: updates in 2013. | Q34404991 | ||
| Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level | Q34481474 | ||
| Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. | Q34500537 | ||
| Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 | ||
| 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. | Q34600796 | ||
| Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. | Q34621209 | ||
| Chronic hepatitis B infection in pregnancy | Q35626775 | ||
| Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update | Q35706189 | ||
| Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B | Q35929532 | ||
| Current treatment of chronic hepatitis B: benefits and limitations | Q36231809 | ||
| Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors | Q37039155 | ||
| Continuous antiretroviral therapy decreases bone mineral density | Q37357149 | ||
| Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. | Q37394366 | ||
| End points of therapy in chronic hepatitis B. | Q37688129 | ||
| Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. | Q37756309 | ||
| Adefovir dipivoxil in chronic hepatitis B: history and current uses | Q37975548 | ||
| Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B. | Q38100847 | ||
| New therapeutic perspectives in HBV: when to stop NAs. | Q38174265 | ||
| Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure. | Q38351585 | ||
| Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients | Q39736089 | ||
| Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance | Q39988589 | ||
| Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians | Q42206668 | ||
| First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment | Q42212031 | ||
| A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. | Q42541246 | ||
| Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. | Q42678962 | ||
| Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline | Q42911213 | ||
| Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels | Q42947260 | ||
| Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. | Q42947269 | ||
| Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma | Q43033643 | ||
| Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection | Q43090210 | ||
| Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. | Q43202400 | ||
| Entecavir in decompensated HBV cirrhosis: the future is looking brighter | Q43223818 | ||
| Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function | Q43235917 | ||
| Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa | Q43279592 | ||
| Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis | Q43493641 | ||
| Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. | Q43645392 | ||
| Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years | Q43914060 | ||
| Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. | Q43925569 | ||
| Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. | Q43951673 | ||
| Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir | Q44038236 | ||
| Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. | Q44079403 | ||
| Histological outcome during long-term lamivudine therapy. | Q44269261 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. | Q44329201 | ||
| Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. | Q44385917 | ||
| Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus | Q44396659 | ||
| Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype | Q44520576 | ||
| Renal safety of tenofovir in HIV treatment-experienced patients. | Q44851246 | ||
| Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient | Q45042778 | ||
| Long-term effect of interferon therapy in patients with HBeAg positive chronic hepatitis B infection | Q45099381 | ||
| Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. | Q45359396 | ||
| Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. | Q45361995 | ||
| Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection | Q45385777 | ||
| Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. | Q45387049 | ||
| Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response | Q45396294 | ||
| Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient | Q45408115 | ||
| Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection | Q45750997 | ||
| Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus | Q45787408 | ||
| Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice | Q46115516 | ||
| Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. | Q46217486 | ||
| Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. | Q46408081 | ||
| Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. | Q46575199 | ||
| Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients | Q46604520 | ||
| Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. | Q46974815 | ||
| A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. | Q46981468 | ||
| Predicting cirrhosis risk based on the level of circulating hepatitis B viral load | Q46985831 | ||
| Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. | Q53211487 | ||
| Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. | Q54377204 | ||
| Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. | Q54549321 | ||
| Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response | Q58097652 | ||
| Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety | Q58235847 | ||
| Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a | Q58376639 | ||
| Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis | Q58803478 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 1457-1468 | |
| P577 | publication date | 2015-09-28 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Monotherapy for hepatitis B infection: a review of treatment options | |
| P478 | volume | 13 |
Search more.